PBAC Recommends First Biologic Obinutuzumab for PBS in Lupus Nephritis
Key Questions
What is the PBAC's recommendation for obinutuzumab in lupus nephritis?
The PBAC has positively recommended obinutuzumab, combined with mycophenolate and steroids, for class III/IV +/- V lupus nephritis. This is the first biologic to gain PBS access, aimed at improving kidney outcomes.
How does obinutuzumab fit with other lupus nephritis treatments?
It complements the PBS subsidy for anifrolumab under section 100. The recommendation aligns with ongoing Australian trials like CAR-T and Enpatoran, supporting broader biologic access.
Why is this PBAC recommendation significant?
It represents the first biologic PBS listing for lupus nephritis, boosting kidney outcomes amid advocacy for swift funding. This aligns with global shifts toward biologics, such as AbbVie's steroid reduction data.
PBAC positive recommendation for obinutuzumab (with mycophenolate/steroids) for class III/IV +/- V lupus nephritis—first biologic PBS access win boosting kidney outcomes. Complements anifrolumab s100 subsidy and aligns with AU CAR-T/Enpatoran trials; advocacy on swift listing amid funding optimism. Aligns with global biologic shifts like AbbVie steroid reduction data.